Anti-PD-1 Therapy in Melanoma

作者：Moreno Blanca Hornet; Parisi Giulia; Robert Lidia; Ribas Anton^*

来源：Seminars in Oncology, 2015, 42(3): 466-473.

DOI：10.1053/j.seminoncol.2015.02.008

Immune-regulatory mechanisms are used by cancer to hide from the immune system. Advances and in-depth understanding of the biology of melanoma and its interaction with the immune system have led to the development of some of antagonistic antibodies to the programmed death 1 pathway (PD-1) and one of its ligands, programmed death ligand 1 (PD-L1), which are demonstrating high clinical benefit rates and tolerability. Blocking the immune-regulatory checkpoints that limit T-cell responses to melanoma upon PD-1/PD-L1 modulation has provided clinically validated targets for cancer immunotherapy. Combinations with other anti-melanoma agents may result in additional benefits. Nivolumab, pembrolizumab (formerly known as MK-3475 and lambrolizumab), and pidilizumab are anti PD-1 antibodies in clinical development for melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck cancers, lymphoma, and several other cancers. Long-term survivors already have been reported with these therapies. In this review, we discuss the current state of anti PD-1 agents, the evidence in the literature to support the combination of anti PD-1 antibodies with other anticancer agents and discuss the future directions for rational design of clinical trials that keep on increasing the number of long-term survivors.

• 出版日期2015-6